Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩3,175, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years. お知らせ • Mar 17
HLB Genex, Inc., Annual General Meeting, Mar 30, 2026 HLB Genex, Inc., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, techno3-ro, yuseong-gu, daejeon South Korea お知らせ • May 22
HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion. HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion on May 21, 2025. A cash consideration of KRW 8.17 billion will be paid by HLB Genex, Inc. for 1,078,841 shares. Upon completion, HLB Genex, Inc. will own 57.83% stake in GF Fermentech Co., Ltd.
For the period ending December 31, 2024, GF Fermentech Co., Ltd. reported total revenue of KRW 19.03 billion and net income of KRW 4.05 billion. As of December 31, 2024, GF Fermentech Co., Ltd. reported total debt of KRW 18.27 billion, total assets of KRW 40.35 billion and total common equity of KRW 22.08 billion.
The expected completion of the transaction is May 26, 2025. New Risk • Mar 30
New major risk - Revenue and earnings growth Earnings have declined by 0.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩103.4b market cap, or US$70.3m). New Risk • Mar 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩98.2b market cap, or US$67.2m). お知らせ • Mar 14
HLB Genex, Inc., Annual General Meeting, Mar 28, 2025 HLB Genex, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 75, techno1-ro, yuseong-gu, daejeon South Korea お知らせ • Dec 13
GenoFocus, Inc. announced that it has received KRW 69.999981686 billion in funding from a group of investors On December 12, 2024 GenoFocus, Inc. closed the transaction. お知らせ • Oct 30
GenoFocus, Inc. announced that it expects to receive KRW 55 billion in funding GenoFocus, Inc. announced a private placement to issue Series 5 Bearer unsecured private placement convertible bonds for a gross proceeds of KRW 55,000,000,000 on October 28, 2024. The bonds a coupon rate of 1% and yield to maturity of 2%. The bonds will mature on December 12, 2027. The bonds will be 100% converted into 17,851,346 common shares at a fixed conversion price of KRW 3,081 per share. The conversion period is from December 12, 2025 to November 12, 2027. The payment date of the transaction is December 12, 2024. The transaction has been approved by the board of directors of the company. The transaction includes participation from Nomad No. 5 Fund for KRW 42,500,000,000, Armart New Technology Fund No. 304 for KRW 9,000,000,000, Lim Jihyun for KRW 3,000,000,000 and The Global Asset Management, Inc. for KRW 500,000,000. お知らせ • Oct 04
Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion. Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion on September 30, 2024. For the period ending December 31, 2023, GF Fermentech Co., Ltd. reported total revenue of KRW 13.88 billion and net income of KRW 10.13 billion, total debt of KRW 34.35 billion, total assets of KRW 52.41 billion and total common equity of KRW 18.06 billion. The expected completion of the transaction is October 4, 2024. New Risk • Aug 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩81.3b market cap, or US$60.0m). Reported Earnings • Mar 21
Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 24
New 90-day low: ₩7,700 The company is down 20% from its price of ₩9,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period. Is New 90 Day High Low • Jan 18
New 90-day low: ₩8,800 The company is down 37% from its price of ₩14,000 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 39% over the same period. Is New 90 Day High Low • Sep 23
New 90-day high: ₩16,900 The company is up 186% from its price of ₩5,900 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period. お知らせ • Aug 30
GenoFocus, Inc. announced that it has received KRW 10 billion in funding On August 24, 2020, GenoFocus, Inc. (KOSDAQ:A187420) closed the transaction. お知らせ • Aug 22
GenoFocus, Inc. announced that it expects to receive KRW 10 billion in funding GenoFocus, Inc. (KOSDAQ:A187420) announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 10,000,000,000 on August 21, 2020. The transaction will include participation from K2 Expedio Fund. The bonds carry a Surface interest rate 0% and interest rate to maturity of 3%. The bonds will mature on August 24, 2025. The bonds can be 100% converted into 1,470,804 common shares for 6.65% stake of the company at a fixed conversion price of KRW 6,799 per share. The conversion period is from August 24, 2021 to July 24, 2025. . The transaction is expected to close by August 24, 2020. The transaction has been approved by the board of directors of the company.